Jonathan Wall is a tenured Professor in the Human Immunology and Cancer Program at the University of Tennessee Graduate School of Medicine, Knoxville, TN. He graduated from the University of Essex (Colchester, UK) with a baccalaureate in biological sciences and moved to the department of Biological Chemistry and Biophysics to pursue a PhD in membrane biophysics, during which time he studied the interactions of proteins with model membrane systems under the tutelage of Prof. Paul O’Shea. After graduating he moved to the Human Immunology & Cancer Program at the University of Tennessee Medical Center, as a post-doctoral fellow, where he has worked on elucidating biochemical and biophysical aspects of immunoglobulin light chain amyloidosis. His work led to the “first-in-human” clinical trial studying the biodistribution, by using PET/CT imaging, of a novel radio-iodinated amyloid fibril-reactive monoclonal antibody in patients with light chain amyloidosis. In addition, he leads an NIH-funded multidisciplinary team of researchers focused on developing novel therapeutic and molecular imaging agents for amyloid disease, type 2 diabetes, and cancer. Dr. Wall was appointed Director of the Preclinical and Diagnostic Molecular Imaging Program at the University of Tennessee Graduate School of Medicine which specializes in using high-resolution, multi-modality micro-imaging technology for visualizing metabolic, pathologic and anatomic features in small animal models of disease.
Focus Areas: Protein Folding Disorders | Amyloidosis | Molecular (PET/SPECT) Imaging | Peptide Radiotracers | Translational Research
Skills and Expertise: Molecular (SPECT) Imaging | Protein-Protein Interactions | Peptide Radiotracers